<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nexgel, Inc — News on 6ix</title>
<link>https://6ix.com/company/nexgel-inc</link>
<description>Latest news and press releases for Nexgel, Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 12 May 2026 14:27:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nexgel-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a4f578dffbe2df10ae29.webp</url>
<title>Nexgel, Inc</title>
<link>https://6ix.com/company/nexgel-inc</link>
</image>
<item>
<title>NEXGEL To Report First Quarter 2026 Financial Results on May 15th</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-to-report-first-quarter-2026-financial-results-on-may-15th</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-to-report-first-quarter-2026-financial-results-on-may-15th</guid>
<pubDate>Tue, 12 May 2026 14:27:00 GMT</pubDate>
<description>Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2026 ended March 31, 2026, on Friday, May 15, 2026. Following th</description>
</item>
<item>
<title>NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-appoints-brian-kieser-and-kevin-harris-from-new-strategic-partner-sequence-lifesciencetm-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-appoints-brian-kieser-and-kevin-harris-from-new-strategic-partner-sequence-lifesciencetm-to-board-of-directors</guid>
<pubDate>Wed, 06 May 2026 04:00:00 GMT</pubDate>
<description>Sequence LifeScienceTM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE</description>
</item>
<item>
<title>NEXGEL Appoints Ian Blackman as Chief Financial Officer</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-appoints-ian-blackman-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-appoints-ian-blackman-as-chief-financial-officer</guid>
<pubDate>Mon, 27 Apr 2026 13:00:00 GMT</pubDate>
<description>Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Ian Blackman, CPA, as Chief Financial Officer. Mr.</description>
</item>
<item>
<title>NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-new-strategic-partner-sequence-lifesciencetm-leads-financing-with-dollar55-million-to-complete-acquisition-of-celularity-degenerative-disease-segment</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-new-strategic-partner-sequence-lifesciencetm-leads-financing-with-dollar55-million-to-complete-acquisition-of-celularity-degenerative-disease-segment</guid>
<pubDate>Tue, 21 Apr 2026 13:00:00 GMT</pubDate>
<description>Transaction expected to approximately triple NEXGEL’s annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Forms BioNX Surgical, a division of NEXGEL LANGHORNE, Pa. , April 21, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the</description>
</item>
<item>
<title>Celularity Announces Closing of Transaction with NexGel</title>
<link>https://6ix.com/company/nexgel-inc/news/celularity-announces-closing-of-transaction-with-nexgel-1</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/celularity-announces-closing-of-transaction-with-nexgel-1</guid>
<pubDate>Tue, 21 Apr 2026 12:30:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously announced transaction with NexGel, Inc. (“NexGel”), pursuant to which NexGel acquired certain commercial and other assets related to Celularity’s biomaterials product portfolio and received an exclusive license to develop and commercialize specified products. The transaction is intended</description>
</item>
<item>
<title>NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-moves-forward-shareholder-update-call-to-discuss-celularity-transaction-on-april-21st-at-430-pm-et</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-moves-forward-shareholder-update-call-to-discuss-celularity-transaction-on-april-21st-at-430-pm-et</guid>
<pubDate>Fri, 17 Apr 2026 19:37:00 GMT</pubDate>
<description>LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it is moving up its shareholder update conference call from Thursday, April 23rd to Tuesday, April 21st, 2026, at 4:30 P.M. ET. Shareholder Update Call Details:Date: April 21, 2026Time: 4:30 P.</description>
</item>
<item>
<title>NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-reschedules-shareholder-update-conference-call-to-april-23rd-at-430-pm-et-to-provide-update-on-celularity-transaction</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-reschedules-shareholder-update-conference-call-to-april-23rd-at-430-pm-et-to-provide-update-on-celularity-transaction</guid>
<pubDate>Wed, 15 Apr 2026 20:12:00 GMT</pubDate>
<description>LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 23, 2026, at 4:30 P.M. ET. While there is no assurance that the Celularity transaction will close, the Company will not be fi</description>
</item>
<item>
<title>NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-reschedules-shareholder-update-conference-call-to-april-15th-at-430-pm-et-to-provide-update-on-celularity-transaction</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-reschedules-shareholder-update-conference-call-to-april-15th-at-430-pm-et-to-provide-update-on-celularity-transaction</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and</description>
</item>
<item>
<title>NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-reschedules-2025-financial-results-conference-call-to-april-8th-at-430-pm-et-to-provide-shareholders-with-an-update-on-its-previously-announced-transaction-with-celularity</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-reschedules-2025-financial-results-conference-call-to-april-8th-at-430-pm-et-to-provide-shareholders-with-an-update-on-its-previously-announced-transaction-with-celularity</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and</description>
</item>
<item>
<title>NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-31st</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-31st</guid>
<pubDate>Wed, 25 Mar 2026 13:00:00 GMT</pubDate>
<description>Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the market close</description>
</item>
<item>
<title>NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-announces-consideration-terms-of-agreement-to-license-and-acquire-portfolio-of-commercial-stage-regenerative-biomaterial-products-12</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-announces-consideration-terms-of-agreement-to-license-and-acquire-portfolio-of-commercial-stage-regenerative-biomaterial-products-12</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net</description>
</item>
<item>
<title>NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-signs-definitive-agreement-to-license-and-acquire-transformative-portfolio-of-commercial-stage-regenerative-biomaterial-products-6</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-signs-definitive-agreement-to-license-and-acquire-transformative-portfolio-of-commercial-stage-regenerative-biomaterial-products-6</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon</description>
</item>
<item>
<title>NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-announces-financing-1-797-140000830</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-announces-financing-1-797-140000830</guid>
<pubDate>Tue, 10 Feb 2026 14:00:00 GMT</pubDate>
<description>LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the financing of $1.797 million relating to a potential acquisition targeted for the first quarter of 2026. The potential acquisition is subject to the completion of due diligence by both NEXGEL</description>
</item>
<item>
<title>NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgelrx-receives-additional-investment-eric-130000711</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgelrx-receives-additional-investment-eric-130000711</guid>
<pubDate>Tue, 16 Dec 2025 13:00:00 GMT</pubDate>
<description>LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that NexGelRx, the Company’s previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, L</description>
</item>
<item>
<title>NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-announces-spin-off-drug-130000863</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-announces-spin-off-drug-130000863</guid>
<pubDate>Thu, 11 Dec 2025 13:00:00 GMT</pubDate>
<description>NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also receive a 5% global royalty in perpetuity on products sold using its drug delivery technology LANGHORNE, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for hea</description>
</item>
<item>
<title>NEXGEL Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-reports-third-quarter-2025-211000198</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-reports-third-quarter-2025-211000198</guid>
<pubDate>Tue, 11 Nov 2025 21:10:00 GMT</pubDate>
<description>LANGHORNE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its third quarter 2025 financial results for the period ending September 30, 2025. Third Quarter 2025 Financial Highlights: Net Revenue was $2.93 million, compared to $2.94 million in Q3 2024 an</description>
</item>
<item>
<title>NEXGEL to Report Third Quarter 2025 Financial Results on November 11th</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-report-third-quarter-2025-130000356</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-report-third-quarter-2025-130000356</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the third quarter 2025, after the market close on November 11, 2025. Following</description>
</item>
<item>
<title>NEXGEL to Present at the LD Micro Main Event XIX Conference on October 19-21</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-present-ld-micro-main-120000487</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-present-ld-micro-main-120000487</guid>
<pubDate>Thu, 09 Oct 2025 12:00:00 GMT</pubDate>
<description>LANGHORNE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the LD Micro Main Event XIX Conference being held at the Hotel Del Coronado in San Diego, California, on October 19-21, 2025. LD Micro Ma</description>
</item>
<item>
<title>NEXGEL Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-reports-second-quarter-2025-200500683</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-reports-second-quarter-2025-200500683</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-co</description>
</item>
<item>
<title>NEXGEL to Report Second Quarter 2025 Financial Results on August 12th</title>
<link>https://6ix.com/company/nexgel-inc/news/nexgel-report-second-quarter-2025-120000639</link>
<guid isPermaLink="true">https://6ix.com/company/nexgel-inc/news/nexgel-report-second-quarter-2025-120000639</guid>
<pubDate>Wed, 06 Aug 2025 12:00:00 GMT</pubDate>
<description>Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2025, after the market close on August 12, 2025. Following the release of its financial results, the Company will host a conferen</description>
</item>
</channel>
</rss>